Format

Send to

Choose Destination
Oncotarget. 2014 Nov 15;5(21):10665-77.

Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer.

Author information

1
Department of Pharmacology, Baylor College of Medicine, Houston, TX 77030, USA.
2
Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
3
Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX 77030, USA.
4
Department of Pharmacology, Baylor College of Medicine, Houston, TX 77030, USA. Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.

Abstract

Histone lysine methylation regulates gene expression and cancer initiation. Bioinformatics analysis suggested that DOT1L, a histone H3-lysine79 (H3K79) methyltransferase, plays a potentially important role in breast cancer. DOT1L inhibition selectively inhibited proliferation, self-renewal, metastatic potential of breast cancer cells and induced cell differentiation. In addition, inhibitors of S-adenosylhomocysteine hydrolase (SAHH), such as neplanocin and 3-deazaneplanocin, also inhibited both H3K79 methylation and proliferation of breast cancer cells in vitro and in vivo. The activity of SAHH inhibitors was previously attributed to inhibition of H3K27 methyltransferase EZH2. However, inhibition of EZH2 by a specific inhibitor did not contribute to cell death. SAHH inhibitors had only weak activity against H3K27 methylation and their activity is therefore mainly due to DOT1L/H3K79 methylation inhibition. Overall, we showed that DOT1L is a potential drug target for breast cancer.

PMID:
25359765
PMCID:
PMC4279401
DOI:
10.18632/oncotarget.2496
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center